Management of Progressive Disease in Idiopathic Pulmonary Fibrosis
NCT ID: NCT03939520
Last Updated: 2024-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
378 participants
INTERVENTIONAL
2020-06-11
2026-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Recently two disease-modifying therapies, pirfenidone and nintedanib, have been approved worldwide. Both drugs reduce the disease progression as measured by progressive decline in forced vital capacity (FVC), with a reduction of overall mortality showed by meta-analysis of phase III pirfenidone trials.
However, progression of disease continues to occur despite the currently available drug therapy. Many patients die from progressive, chronic hypoxemic respiratory failure, or less frequently from acute exacerbation of pulmonary fibrosis. In these patients, no data are available to guide management between continuation of the prescribed antifibrotic drug, to switch to the other available antifibrotic drug, or to combine the available drugs.
The combination of nintedanib and pirfenidone is not recommended outside clinical trials. However, although both antifibrotic drugs were developed and approved as monotherapy, two recent trials have suggested the feasibility and safety of combining them over a 12-24 weeks period. These results encourage further studies of combination treatment with pirfenidone and nintedanib in patients with IPF. Such study is timely, as there is a risk that clinicians facing the continued worsening of disease in patients receiving one of the available drugs may prescribe both drugs combined outside clinical trials, potentially exposing patients to a currently unknown risk.
This study will evaluate the efficacy and tolerance of the combination pirfenidone and nintedanib as compared to a "switch monotherapy": i.e. switching from the current to the other of the two existing drugs prescribed as monotherapy, in patients who present chronic worsening IPF despite receiving either pirfenidone or nintedanib and as to a "control group": i.e.treatment still be on as before randomization (pirfenidone or nintedanib).
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Combined therapy
pirfenidone and nintedanib
The experimental group will receive pirfenidone 2403 mg per day (at least 1602 mg) in combination with nintedanib 300 mg per day (at least 200 mg) during 24 weeks.
Switch monotherapy
pirfenidone or nintedanib
The second intervention group will switch from one monotherapy during 24 weeks: with pirfenidone 2403 mg per day (at least 1602 mg) or nintedanib 300 mg per day (at least 200 mg) to the other monotherapy (nintedanib in patients who received pirfenidone as first line therapy before inclusion and conversely).
Control group
pirfenidone or nintedanib
The control group will keep on the same monotherapy during 24 weeks: with pirfenidone 2403 mg per day (at least 1602 mg) or nintedanib 300 mg per day (at least 200 mg) to the other monotherapy (nintedanib in patients who received pirfenidone as first line therapy before inclusion and conversely).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pirfenidone and nintedanib
The experimental group will receive pirfenidone 2403 mg per day (at least 1602 mg) in combination with nintedanib 300 mg per day (at least 200 mg) during 24 weeks.
pirfenidone or nintedanib
The second intervention group will switch from one monotherapy during 24 weeks: with pirfenidone 2403 mg per day (at least 1602 mg) or nintedanib 300 mg per day (at least 200 mg) to the other monotherapy (nintedanib in patients who received pirfenidone as first line therapy before inclusion and conversely).
pirfenidone or nintedanib
The control group will keep on the same monotherapy during 24 weeks: with pirfenidone 2403 mg per day (at least 1602 mg) or nintedanib 300 mg per day (at least 200 mg) to the other monotherapy (nintedanib in patients who received pirfenidone as first line therapy before inclusion and conversely).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with Idiopathic Pulmonary Fibrosis satisfying the ATS/ERS/JRS/ALAT diagnostic criteria (29) diagnosed.
In the absence of a surgical lung biopsy, high-resolution computed tomography (HRCT) must be "consistent with Usual Interstitial Pneumonia (UIP)" defined as meeting either criteria A, B, and C, or criteria A and C, or criteria B and C below:
A. Definite honeycomb lung destruction with basal and peripheral predominance. B. Presence of reticular abnormality and traction bronchiectasis consistent with fibrosis, with basal and peripheral predominance.
C. Atypical features are absent, specifically nodules and consolidation. Ground glass opacity, if present, is less extensive than reticular opacity pattern.
* \- Patient who fulfill at least 1 of the 4 criteria for IPF progression in the 12 months (+/- one six months) before screening, despite antifibrotic treatment in clinical practice (if yes check the option(s)). These criteria are: 0 Relative decline in FVC ≥10% predicted 0 Relative decline in FVC ≥5-\<10% predicted and worsened respiratory symptoms 0 Relative decline in FVC ≥5-\<10% predicted and increased extent of fibrotic changes on chest imaging 0 Worsened respiratory symptoms and increased extent of fibrotic changes on chest imaging
* Patient must have been on a stable dose of pirfenidone or nintedanib prescribed as first-line therapy for at least 6 months, with good tolerance of 1602 to 2403 mg per day of pirfenidone or 200 to 300 mg per day of nintedanib.
* Patient who has a FVC ≥ 45% of predicted.
* Patient who has a forced expiratory volume in 1 second (FEV1)/FVC ratio \> 0.70.
* Patient who has a life expectancy of at least 9 months.
* Patient who has provided his written informed consent to participate in the study.
* Patient affiliated to a social insurance regimen.
Exclusion Criteria
* Female patient who is pregnant or lactating, or is of child bearing potential (defined as a sexually mature woman not surgically sterilized or not post-menopausal for at least 24 consecutive months if ≤ 55 years or 12 months if \> 55 years) and who did not agree to use highly effective methods of birth control throughout the study.
* Patient who is currently on both pirfenidone and nintedanib.
* Patient who has already received pirfenidone and nintedanib either concomitantly or successively.
* Patient who has a contra-indication to pirfenidone or nintedanib.
* Patient who has emphysema \> 15% on HRCT or the extent of emphysema is greater than the extent of fibrosis according to reported results from the most recent HRCT.
* Patient who had acute exacerbation of idiopathic pulmonary fibrosis within the previous 3 months.
* Patient who has a history of cigarette smoking within the previous 3 months.
* Patient who has received experimental therapy for IPF within 4 weeks before baseline.
* Patient who is receiving systemic corticosteroids equivalent to prednisone \> 15 mg/day or equivalent within 2 weeks before baseline.
* Patient who received Immuno-suppressants (e.g. methotrexate, azathioprine, cyclophosphamide, cyclosporine, sirolimus, everolimus or other immunosuppressants) within 4 weeks before baseline.
* Patient who has a history of a malignancy within the previous 5 years, with the exception of basal cell skin neoplasms. In addition, a malignant diagnosis or condition first occurring prior to 5 years must be considered cured, inactive, and not under current treatment.
* Patient who, in the Investigator's opinion, is not able to perform home spirometry in accordance with the protocol.
* Patient who has any concurrent condition other than IPF that, in the Investigator's opinion, is unstable and/or would impact the likelihood of survival for the study duration or the subject's ability to complete the study as designed, or may influence any of the safety or efficacy assessments included in the study.
* Patient who has baseline resting oxygen saturation of \< 88% on room air or supplemental oxygen.
* Patient who had lung transplantation or who is on a lung transplant list and the investigator anticipates the patient will not be able to complete the study prior to transplant.
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vincent COTTIN, Pr
Role: PRINCIPAL_INVESTIGATOR
Hospices Civils de Lyon
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU d'Angers
Angers, , France
Centre Hospitalier de la côte Basque
Bayonne, , France
CHRU de Besançon - Hôpital Jean Minjoz
Besançon, , France
AP - HP - Hôpital Avicenne
Bobigny, , France
CHRU Hôpital Cavale Blanche
Brest, , France
Hôpital Pneumologique et Cardiovasculaire Louis Pradel
Bron, , France
CHU de Caen - Hôpital de la Côte de Nacre
Caen, , France
CHU Dijon Bourgogne - Hôpital François Mitterrand
Dijon, , France
CHRU de Lille - Hôpital Albert Calmette
Lille, , France
CHU de Marseille - Hôpital Nord
Marseille, , France
CHRU de Montpellier - Hôpital Arnaud de Villeneuve
Montpellier, , France
CHU - Hôpital G.R. Laennec
Nantes, , France
CHU de Nice, Hôpital Pasteur
Nice, , France
APHP - Hôpital Xavier Bichat-Claude Bernard
Paris, , France
Groupe Hospitalier Paris Saint Joseph
Paris, , France
Ch de Cornouaille
Quimper, , France
CHU Rennes - Hôpital Pontchaillou
Rennes, , France
CHU de Toulouse - Hôpital Larrey
Toulouse, , France
CHRU, Tours - Hôpital Bretonneau
Tours, , France
CHU Nancy - Hôpital Brabois
Vandœuvre-lès-Nancy, , France
Hôpital Robert Schuman
Vantoux, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Frédéric GAGNADOUX
Role: primary
Pierre RIGAUD
Role: primary
Mathilde DUPREZ
Role: primary
Hilario NUNES
Role: primary
Aude BARNIER
Role: primary
Emmanuel BERGOT
Role: primary
Philippe BONNIAUD
Role: primary
Lidwine WEMEAU-STERVINOU
Role: primary
Martine REYNAUD-GAUBERT
Role: primary
Anne-Sophie GAMEZ
Role: primary
Stéphanie DIROU
Role: primary
Charles-Hugo MARQUETTE
Role: primary
Bruno CRESTANI
Role: primary
Jean-Marc NACCACHE
Role: primary
Nicolas BIZIEN, Dr
Role: primary
Stéphane JOUNEAU
Role: primary
Grégoire PRÉVOT
Role: primary
Laurent PLANTIER
Role: primary
Anne GUILLAUMOT
Role: primary
Benoit GODBERT
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-004326-19
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
69HCL19_0029
Identifier Type: -
Identifier Source: org_study_id